Pharmacologic treatments for covid-19 patients

Analyses are updated every Friday

Methods

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Search by treatment name :

Display new or updated analyses

Display all results

Your research: comparisons updated with new studies

Access the forest plots for the 2 treatment comparisons .

    Monoclonal antibodies (2 comparisons)

General characteristics of primary studies

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04412772
ARCHITECTS, Unpublished, 2021
Public/non profit Tocilizumab Placebo RCT Patients with confirmed COVID-19 (critical) admitted to a single center in the USA. N=21
Low
Details

Full description

NCT04324073
CORIMUNO-SARI, Unpublished, 2021
Public/non profit Standard care Sarilumab RCT Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to multiple centers in France. N=*
Low
Details

Full description

NCT04331808
CORIMUNO-TOCI-2 (ICU), Unpublished, 2021
Public/non profit Standard care Tocilizumab RCT Patients with suspected or confirmed COVID-19 (severe-critical) admitted to multiple centers in France. N=*
Low
Details

Full description

NCT04330638
COV-AID, Unpublished, 2021
Public/non profit Tocilizumab Standard care RCT Patients with suspected or confirmed COVID-19 (severe-critical) admitted to 16 centers in Belgium N=153
Low
Details

Full description

NCT04479358
COVIDOSE-2, Unpublished, 2021
Public/non profit Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to multiple centers in the USA N=28
Low
Details

Full description

NCT04577534
COVIDSTORM, Unpublished, 2021
Not reported/unclear Standard care Tocilizumab RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Finland. N=39
Low
Details

Full description

NCT04435717
COVITOZ-01, Unpublished, 2021
Public/non profit Standard care Tocilizumab RCT Patients with suspected or confirmed COVID-19 (mild-moderate-severe) admitted to a single center in Spain. N=26
Low
Details

Full description

NCT02735707
Derde L, REMAP-CAP, 2021
Full text
Commentary
Commentary
Mixed Tocilizumab Standard care RCT Patients with suspected or confirmed COVID-19 (moderate to critical) admitted to 133 centers in 9 countries N=2253
Some concerns
Details

Full description

Sarilumab Standard care
Anakinra Standard care
NCT02735707
Gordon AC, REMAP-CAP, 2021
Full text
Commentary
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed or suspected COVID-19 (severe-critical) admitted to 113 centers in Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK. N=826
Some concerns
Details

Full description

Sarilumab Standard care
NCT04331808
Hermine O, JAMA Intern Med, 2020
Full text
Commentary
Public/non profit Tocilizumab Standard care RCT Patients with COVID-19 (moderate-severe) admitted to nine centers in France N=131
Some concerns
Details

Full description

NCT04377750
HMO-0224-20, Unpublished, 2021
Public/non profit Placebo Tocilizumab RCT Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in Israel. N=54
High
Details

Full description

NCT04381936, ISRCTN50189673
Horby P, Lancet, 2021
Full text
Commentary
Commentary
Public/non profit Tocilizumab Standard care RCT Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 131 centers in the UK N=4116
Some concerns
Details

Full description

NCT04412291, EudraCT 2020-001748-24
IMMCOVA, Unpublished, 2021
Public/non profit Standard care Tocilizumab RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a multiple centerd in Sweden N=49
Low
Details

Full description

NCT04327388; EudraCT2020-001162-12; U1111-1249-602
Lescure FX, 2021
Full text
Commentary
Commentary
Private Sarilumab 400mg Placebo RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 45 centers in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. N=420
Some concerns
Details

Full description

Sarilumab 200mg Placebo
Sarilumab 400mg Sarilumab 200mg
NCT04409262
REMDACTA, Unpublished, 2021
Private Placebo Tocilizumab RCT Patients with confirmed COVID-19 (severe-critical) admitted to a multiple centers in Spain, USA, Brazil and Russia. N=640
Some concerns
Details

Full description

NCT04320615
Rosas I, N Engl J Med, 2021
Full text
Commentary
Mixed Tocilizumab Placebo RCT Patients with confirmed COVID-19 (mild-critical) admitted to multiple centers across 9 countries N=452
Low
Details

Full description

Trial NL8504
Rutgers A, SSRN, 2021
Full text
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 11 centers in the Netherlands. N=354
Some concerns
Details

Full description

NCT04372186
Salama C, N Engl J Med, 2020
Full text
Full text
Commentary
Commentary
Private Tocilizumab Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to 65 centers in Brazil, Kenya, Mexico, Peru, South Africa, and USA N=388
Some concerns
Details

Full description

NCT04346355
Salvarani C, JAMA , 2020
Full text
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed COVID-19 (severe) admitted to 24 centers in Italy N=126
Some concerns
Details

Full description

NCT04357808
SARCOVID, Unpublished, 2021
Mixed Sarilumab Standard care RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Spain. N=30
Low
Details

Full description

NCT04357860, EU-CTR 2020-001531-27
SARICOR, Unpublished, 2021
Public/non profit Sarilumab Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to 10 centers in Spain N=115
Low
Details

Full description

EU-CTR 2020-002037-15
SARTRE, Unpublished, 2021
Private Sarilumab Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 5 centers in Spain N=140
Low
Details

Full description

NCT04315298
Sivapalasingam S (1), 2021
Full text
Commentary
Commentary
Private Sarilumab 400mg Placebo RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 56 centers in the USA N=457
Some concerns
Details

Full description

Sarilumab 200mg Placebo
Sarilumab 400mg Sarilumab 200mg
NCT04315298
Sivapalasingam S (2), 2021
Full text
Commentary
Commentary
Private Sarilumab 400mg Placebo RCT Patients with confirmed COVID-19 (moderate-severe-critical) admitted to 56 centers in the USA N=1330
Some concerns
Details

Full description

Sarilumab 200mg Placebo
Sarilumab 400mg Sarilumab 200mg
CTRI/2020/05/025369
Soin AS, Lancet Respir Med, 2021
Full text
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 12 centers in India N=180
Some concerns
Details

Full description

NCT04356937
Stone JH, N Engl J Med, 2020
Full text
Commentary
Private Tocilizumab Placebo RCT Patients with COVID-19 (mild-severe) admitted to seven centers in USA N=243
Low
Details

Full description

IRCT20081027001411N4
Talaschian M, Research Square, 2021
Full text
Commentary
Commentary
Public/non profit Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran N=40
High
Details

Full description

NCT04332094, EudraCT 2020-001442-19
TOCOVID, Unpublished, 2021
Public/non profit Standard care Tocilizumab RCT Patients with confirmed COVID-19(mild-moderate) admitted to multiple centers in Spain. N=270
Low
Details

Full description

NCT04324073

Unpublished, 2021
Public/non profit Sarilumab Standard care RCT Patients with suspected or confirmed COVID-19 (severe-critical) admitted to multiple centers in France. N=*
Some concerns
Details

Full description

NCT04403685
Veiga VC, BMJ, 2021
Full text
Commentary
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 9 centers in Brazil N=129
Some concerns
Details

Full description

ChiCTR2000029765
Wang D, Front Med, 2021
Full text
Full text
Commentary
Public/non profit Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 6 centers in China N=65
Some concerns
Details

Full description